Evidence map›Paper›PMID 38253080›Full record

ArticleZhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology2023

[Progress and application of liver organoids in the study of liver cancer].

M Wang, Z Y Xu, C Yu, X Y Zhang, H Y Cao, Y Ma

Abstract readEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Article in Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

M WangDepartment of Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, China.
Z Y XuDepartment of Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, China.
C YuDepartment of Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, China.
X Y ZhangDepartment of Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, China.
H Y CaoDepartment of Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, China.
Y MaDepartment of Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210000, China.

Funding

China Postdoctoral Science Foundation 2022M721667
6 · The paper itself

Abstract

The incidence rate of liver cancer has been rising in recent years. Traditional cell line culture and human patient-derived tumor xenograft models, which are commonly used tools to simulate the occurrence of human liver cancer, have deepened the understanding of tumor occurrence, development, and drug resistance mechanisms. However, they cannot reflect the accurate state of cancer cells, the tumor microenvironment, or spatial structural characteristics. Recently, more in vitro-produced physiological liver organoids have been applied in the study of liver cancer. Liver organoid models have made breakthroughs in the occurrence and development mechanisms of liver cancer, personalized drug screening and biomarker identification, immunotherapy, and regenerative medicine applications. This paper mainly summarizes the progress and application of liver organoids processed in the study of liver cancer.

Indexed as

Liver NeoplasmsAnimalsCell Culture TechniquesCell LineDisease Models, AnimalHumansOrganoidsTumor MicroenvironmentOrganoidsPrimary hepatic carcinomaStem cells

Identifiers

PMID38253080
PMCPMC12814730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.